Biotechnology company developing psychedelic-based pharmaceuticals for rare diseases and mental disorders Akome Biotech Ltd has filed a provisional patent application for development of a next generation psychedelic drug formulation aimed to mitigate neurological damage which emanate from ischemic strokes.
The drug formulation for mitigating neurological damage arising from ischemic stroke is called AKO001. The drug comprises of psychedelic compound N-dimethyltryptamine (DMT) and a particular bioactive plant which when combined together are believed to work in a complementary and mitigating manner when administered to people immediately after their ischemic stroke.
Ischemic is a condition whereby blood vessels become blocked and flow of blood is reduced or stopped completely. When a body part is receiving reduced blood flow, it means that the part is not receiving adequate oxygen.
Most strokes are ischemic by nature, flow of blood through the artery that supplies oxygenated blood to the brain becomes blocked and brain cells begin to die.
Ischemic stroke is third most leading cause of death across the world and it also results to disability among adults. According to data compiled by the World Health Organization (WHO) an estimated 17.9 million people die from stoke worldwide each year.
“Our goal with the development of AKO001 is to reduce the damage from the number of lifelong disabling symptoms that can occur after experiencing a stroke. We look forward to continued development on this front and providing updates to the medical community on our progress,” said the company’s CEO, Joel Shacker.
The company filed this patent application with the United States Patent and Trademark Office (UPTSO) under the application 63147343.
